KYOTO, Japan — Eculizumab (Soliris, Alexion Pharmaceuticals) is safe for the treatment of patients with severe Guillain-Barré syndrome (GBS), a new phase 2 study shows. However, although more patients ...

Biopharmaceutical company Annexon (ANNX) is showing promising results in developing treatments for inflammatory-related diseases. Its flagship candidate, ANX005, showed positive topline Phase 3 data ...

SAN DIEGO -- A single dose of investigational tanruprubart resulted in rapid, sustained improvement in disability compared with placebo in patients with Guillain-Barré syndrome (GBS), a phase III, ...

BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (ANNX) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with ...

Guillain-?Barr Syndrome is a rare condition in which a person's immune system attacks the peripheral nerves. People affected suffer from muscle weakness and paralysis. A research team led by ETH ...

Sufjan Stevens has revealed that he is currently undergoing intensive treatment for Guillain-Barré syndrome—a rare auto-immune disorder in which the body’s immune system attacks the nerves. In a post ...

In endemic areas, dengue-related Guillain-Barre syndrome could be a 'substantial and underrecognized component of the ...

A 53 year old man from Mumbai has died due to Guillain-Barré Syndrome (GBS) at a hospital in Mumbai, making it the first death in the metropolis. The resident of Mumba's Wadala area was working as a ...

Brazil: Brazilian researchers have found in a new study, published in The New England Journal of Medicine, that dengue ...